Patents by Inventor Peter Palese
Peter Palese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6669943Abstract: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: June 11, 1999Date of Patent: December 30, 2003Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Peter Palese, Adolfo Garcia-Sastre, Thomas Muster
-
Patent number: 6649372Abstract: The present invention relates methods of generating infectious negative-strand virus in host cells by an entirely vector-based system without the aid of a helper virus. In particular, the present invention relates methods of generating infectious recombinant negative-strand RNA viruses intracellularly in the absence of helper virus from expression vectors comprising cDNAs encoding the viral proteins necessary to form ribonucleoprotein complexes (RNPs) and expression vectors comprising cDNA for genomic viral RNA(s) (vRNAs) or the corresponding cRNA(s). The present invention also relates to methods of generating infectious recombinant negative-strand RNA viruses which have mutations in viral genes and/or which express, package and/or present peptides or polypeptides encoded by heterologous nucleic acid sequences.Type: GrantFiled: November 28, 2000Date of Patent: November 18, 2003Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Peter Palese, Adolfo Garcia-Sastre, George G. Brownlee, Ervin Fodor
-
Publication number: 20030157131Abstract: The present invention relates to genetically engineered attenuated viruses and methods for their production. In particular, the present invention relates to engineering live attenuated viruses which contain a modified NS gene segment. Recombinant DNA techniques can be utilized to engineer site specific mutations into one or more noncoding regions of the viral genome which result in the down-regulation of one or more viral genes. Alternatively, recombinant DNA techniques can be used to engineer a mutation, including but not limited to an insertion, deletion, or substitution of an amino acid residue(s) or an epitope(s) into a coding region of the viral genome so that altered or chimeric viral proteins are expressed by the engineered virus.Type: ApplicationFiled: December 9, 2002Publication date: August 21, 2003Applicant: Mount Sinai School of MedicineInventors: Andrei Egorov, Thomas Muster, Adolfo Garcia-Sastre, Peter Palese, Sabine Brandt
-
Patent number: 6573079Abstract: The present invention relates, to novel methods and substrates for the propagation of viruses. The invention relates to IFN-deficient substrates and methods for propagating viruses in these unconventional substrates. In particular, the invention relates to methods of propagating viruses in immature embryonated eggs, preferably six- to nine-day-old chicken eggs. The methods of the invention are particularly attractive for growing viruses suitable for use in vaccine and pharmaceutical formulations.Type: GrantFiled: June 11, 1999Date of Patent: June 3, 2003Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Peter Palese, Adolfo García-Sastre, Robert O'Neil
-
Publication number: 20030083305Abstract: The present invention relates to compositions comprising one or more viral interferon antagonists and methods of utilizing said compositions to modulate the cellular interferon immune response. In particular, the present invention relates to pharmaceutical compositions comprising one or more viral interferon antagonists and methods of utilizing said compositions to prevent, treat or ameliorate an immune disorder characterized by aberrant interferon expression and/or activity. The invention also relates to methods of treating, preventing or ameliorating the symptoms of an inflammatory disorder comprising administering to a subject in need thereof one or more viral interferon antagonist. The present invention also relates to compositions comprising fusion proteins comprising one or more viral interferon antagonists and a heterologous polypeptide, and methods of using said compositions to modulate the cellular interferon immune response.Type: ApplicationFiled: October 10, 2002Publication date: May 1, 2003Inventors: Peter Palese, Adolfo Garcia-Sastre
-
Publication number: 20030078410Abstract: This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral RNA templates which may be used with viral RNA-directed RNA polymerase to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. In a specific embodiment of the invention, the heterologous gene product is a peptide or protein derived from the genome of a human immunodeficiency virus. The RNA templates of the present invention may be prepared by transcription of appropriate DNA sequences using any DNA-directed RNA polymerase such as bacteriophage T7, T3, SP6 polymerase, or eukaryotic polymerase I.Type: ApplicationFiled: September 17, 2002Publication date: April 24, 2003Applicant: Mount Sinai School of Medicine of New York UniversityInventors: Adolfo Garcia-Sastre, Peter Palese
-
Patent number: 6544785Abstract: The present invention relates methods of generating infectious negative-strand virus in host cells by an entirely vector-based system without the aid of a helper virus. In particular, the present invention relates methods of generating infectious recombinant negative-strand RNA viruses intracellularly in the absence of helper virus from expression vectors comprising cDNAs encoding the viral proteins necessary to form ribonucleoprotein complexes (RNPs) and expression vectors comprising cDNA for genomic viral RNA(s) (vRNAs) or the corresponding cRNA(s). The present invention also relates to methods of generating infectious recombinant negative-strand RNA viruses which have mutations in viral genes and/or which express, package and/or present peptides or polypeptides encoded by heterologous nucleic acid sequences.Type: GrantFiled: July 14, 2000Date of Patent: April 8, 2003Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Peter Palese, Adolfo Garcia-Sastre, George G. Brownlee
-
Patent number: 6468544Abstract: The present invention relates to genetically engineered attenuated viruses and methods for their production. In particular, the present invention relates to engineering live attenuated viruses which contain a modified NS gene segment. Recombinant DNA techniques can be utilized to engineer site specific mutations into one or more noncoding regions of the viral genome which result in the down-regulation of one or more viral genes. Alternatively, recombinant DNA techniques can be used to engineer a mutation, including but not limited to an insertion, deletion, or substitution of an amino acid residue(s) or an epitope(s) into a coding region of the viral genome so that altered or chimeric viral proteins are expressed by the engineered virus.Type: GrantFiled: June 11, 1999Date of Patent: October 22, 2002Assignee: Mount Sinai School of Medicine of the City University of New YorkInventors: Andrei Egorov, Thomas Muster, Adolfo García-Sastre, Peter Palese, Sabine Brandt
-
Patent number: 6451323Abstract: This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral RNA templates which may be used with viral RNA-directed RNA polymerase to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. In a specific embodiment of the invention, the heterologous gene product is a peptide or protein derived from the genome of a human immunodeficiency virus. The RNA templates of the present invention may be prepared by transcription of appropriate DNA sequences using any DNA-directed RNA polymerase such as bacteriophage T7, T3, SP6 polymerase, or eukaryotic polymerase I.Type: GrantFiled: May 22, 2000Date of Patent: September 17, 2002Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Adolfo Garcia-Sastre, Peter Palese
-
Patent number: 6316243Abstract: The present invention relates to engineering attenuated viruses by altering a non-coding region or the coding sequence of a viral gene. Alterations of the non-coding regions which regulate transcription and/or replication are described. These alterations result in the down-regulation of the viral gene and an attenuation of the virus, either by the production of defective particles during replication, or by reducing the number of progeny virions produced during viral replication. Alterations of viral coding sequences are also described which result in a recombinant or chimeric attenuated virus.Type: GrantFiled: June 6, 1995Date of Patent: November 13, 2001Inventor: Peter Palese
-
Patent number: 6150131Abstract: The present invention relates to assays for the identification of compounds that block palmitylation of influenza virus HA and inhibit virus assembly. In another aspect of the invention, the compounds which inhibit virus assembly, infection and/or replication and which demonstrate a good therapeutic index may be used to treat influenza infection.Type: GrantFiled: March 6, 1997Date of Patent: November 21, 2000Inventor: Peter Palese
-
Patent number: 6146642Abstract: This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral RNA templates which may be used with viral RNA-directed RNA polymerase to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. In a specific embodiment of the invention, the heterologous gene product is a peptide or protein derived from the genome of a human immunodeficiency virus. The RNA templates of the present invention may be prepared by transcription of appropriate DNA sequences using a DNA-directed RNA polymerase such as bacteriophage T7, T3 or the SP6 polymerase.Type: GrantFiled: September 14, 1998Date of Patent: November 14, 2000Assignee: Mount Sinai School of Medicine, of the City University of New YorkInventors: Adolfo Garcia-Sastre, Peter Palese
-
Patent number: 6022726Abstract: The present invention relates to engineering attenuated viruses by altering a non-coding region or the coding sequence of a viral gene. Alterations of the non-coding regions which regulate transcription and/or replication are described. These alterations result in the down-regulation of the viral gene and an attenuation of the virus, either by the production of defective particles during replication, or by reducing the number of progeny virions produced during viral replication. Alterations of viral coding sequences are also described which result in a recombinant or chimeric attenuated virus.Type: GrantFiled: December 20, 1994Date of Patent: February 8, 2000Inventors: Peter Palese, Thomas Muster, Enami Masayoshi, Michael Bergmann
-
Patent number: 6001634Abstract: Recombinant negative-strand viral RNA templates are described which may be used with purified RNA-directed RNA polymerase complex to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. The RNA templates are prepared by transcription of appropriate DNA sequences with a DNA-directed RNA polymerase. The resulting RNA templates are of the negative-polarity and contain appropriate terminal sequences which enable the viral RNA-synthesizing apparatus to recognize the template. Bicistronic mRNAs can be constructed to permit internal initiation of translation of viral sequences and allow for the expression of foreign protein coding sequences from the regular terminal initiation site, or vice versa.Type: GrantFiled: June 29, 1998Date of Patent: December 14, 1999Inventors: Peter Palese, Adolfo Garcia-Sastre
-
Patent number: 5854037Abstract: Recombinant negative-strand viral RNA templates are described which may be used with purified RNA-directed RNA polymerase complex to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. The RNA templates are prepared by transcription of appropriate DNA sequences with a DNA-directed RNA polymerase. The resulting RNA templates are of the negative-polarity and contain appropriate terminal sequences which enable the viral RNA-synthesizing apparatus to recognize the template. Bicistronic mRNAs can be constructed to permit internal initiation of translation of viral sequences and allow for the expression of foreign protein coding sequences from the regular terminal initiation site, or vice versa.Type: GrantFiled: June 1, 1994Date of Patent: December 29, 1998Assignee: The Mount Sinai School of Medicine of the City University of New YorkInventors: Peter Palese, Adolfo Garcia-Sastre
-
Patent number: 5820871Abstract: Recombinant negative-strand viral RNA templates are described which may be sed with purified RNA-directed RNA polymerase complex to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. The RNA templates are prepared by transcription of appropriate DNA sequences with a DNA-directed RNA polymerase. The resulting RNA templates are of the negative-polarity and contain appropriate terminal sequences which enable the viral RNA-synthesizing apparatus to recognize the template. Bicistronic mRNAs can be constructed to permit internal initiation of translation of viral sequences and allow for the expression of foreign protein coding sequences from the regular terminal initiation site, or vice versa.Type: GrantFiled: June 6, 1995Date of Patent: October 13, 1998Assignee: The Mount Sinai School of Medicine of the City University of New YorkInventors: Peter Palese, Adolfo Garcia-Sastre
-
Patent number: 5786199Abstract: Recombinant negative-strand viral RNA templates are described which may be used with purified RNA-directed RNA polymerase complex to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. Heterologous gene products include peptides or proteins derived from HIV which may be presented by a chimeric influenza virus to generate an immune response that is protective against challenge with HIV. A chimeric virus is described which contains an HIV peptide inserted into an influenza protein and which induced both humoral and cell-mediated immune responses against HIV. The RNA templates are prepared by transcription of appropriate DNA sequences with a DNA-directed RNA polymerase. The resulting RNA templates are of the negative-polarity and contain appropriate terminal sequences which enable the viral RNA-synthesizing apparatus to recognize the template.Type: GrantFiled: October 14, 1994Date of Patent: July 28, 1998Assignee: The Mount Sinai School of Medicine of the City University of New YorkInventor: Peter Palese
-
Patent number: 5750394Abstract: The present invention relates to the identification of host cell proteins that interact with viral proteins required for virus replication, and high throughput assays to identify compounds that interfere with the specific interaction between the viral and host cell protein. Interfering compounds that inhibit viral replication can be used therapeutically to treat viral infection.The invention is based, in part, on the discovery described herein of a novel interaction between the NP of influenza virus and a human host cell protein. The host cell protein, referred to herein as NPI-1, may be an accessory protein required for replication of influenza virus. Compounds that interfere with the binding of the host cell and viral proteins, and inhibit viral replication can be useful for treating viral infection in vivo.Type: GrantFiled: May 20, 1994Date of Patent: May 12, 1998Assignee: The Mount Sinai Medical CenterInventors: Peter Palese, Robert O'Neill
-
Patent number: 5637573Abstract: A method of inhibiting influenza virus replication through the activity of natural (unmodified) or modified oligonucleotides (oligodeoxynucleotides or oligoribonucleotides) which hybridize to a selected region of the influenza virus RNA and interfere with its ability to serve as a template for synthesis of encoded products. Oligonucleotides (unmodified or modified) which have antiviral activity against influenza virus as a result of their ability to hybridze to a selected region of influenza virus RNA and inhibit its ability to serve as a template for synthesis of encoded products, as well as compositions which include the oligonucleotides.Type: GrantFiled: June 7, 1995Date of Patent: June 10, 1997Inventors: Sudhir Agrawal, Josef M. E. Leiter, Peter Palese, Paul C. Zamecnik
-
Patent number: 5578473Abstract: Recombinant negative strand virus RNA templates which may be used to express heterologous gene products and/or to construct chimeric viruses are described. Influenza viral polymerase, which was prepared depleted of viral RNA, was used to copy small RNA templates prepared from plasmid-encoded sequences. Template constructions containing only the 3' end of genomic RNA were shown to be efficiently copied, indicative that the promoter lay solely within the 15 nucleotide 3' terminus. Sequences not specific for the influenza vital termini were not copied, and, surprisingly, RNAs containing termini identical to those from plus sense cRNA were copied at low levels. The specificity for recognition of the virus-sense promoter was further defined by site-specific mutagenesis. It was also found that increased levels of vital protein were required in order to catalyze both the cap-endonuclease primed and primer-free RNA synthesis from these model templates as well as from genomic length RNAs.Type: GrantFiled: March 10, 1994Date of Patent: November 26, 1996Assignee: Aviron, Inc.Inventors: Peter Palese, Jeffrey D. Parvin, Mark Krystal